In response to your question, I asked Gemini Advanced 2.0 Flash, one of Google's AI models and got this answer::
what is HCW9218 in the context of IBRX's recent PR about Pancreatic cancer?
From the search results, here's a breakdown of HCW9218 in the context of pancreatic cancer research:
- HCW9218 is an immunotherapy drug:
- It's being tested to counter the effects of senescence, a process that can contribute to cancer relapse, metastasis, and chemotherapy resistance in pancreatic cancer.
- The drug aims to stimulate the immune system and combat immunosuppression, potentially enhancing the effectiveness of chemotherapy. [I have not verified if this is correct.]
- Clinical Trials:
- HCW9218 is undergoing Phase Ib/II clinical trials to assess its safety and tolerability in patients with advanced or metastatic pancreatic cancer.
- The trials involve dose escalation to determine the optimal dosage.
- There has been work done with Phase 1, and Phase 1b trials also.
- Research Goal:
- Researchers hope that HCW9218 will improve the anti-tumor effects of chemotherapy while minimizing its adverse effects on healthy tissues.
- It is being evaluated by companies such as ImmunityBio, and HCW Biologics.
In summary, HCW9218 is an investigational immunotherapy being studied for its potential to improve outcomes for patients with advanced pancreatic cancer, particularly in conjunction with chemotherapy.
How is it related to Does anyone know if it is related to NCT05304936? I
Yes, HCW9218 is directly related to the clinical trial registered as NCT05304936. Here's how:
- NCT05304936 is a clinical trial for HCW9218:
- Specifically, NCT05304936 is a Phase 1b/2 clinical trial designed to evaluate the safety and efficacy of HCW9218 in patients with advanced pancreatic cancer.
- This trial is sponsored by HCW Biologics, the company developing the drug.
- Purpose of the trial:
- The trial aims to assess how well HCW9218 works in patients whose pancreatic cancer has become resistant to or no longer responds to chemotherapy.
- Therefore, the clinical trial number NCT05304936, is the identifier for the specific trial that is testing the drug HCW9218, on patients with advanced pancreatic cancer.
In essence, NCT05304936 is the official registration of the clinical trial that is studying HCW9218 in pancreatic cancer patients.
See IBRX SEC filing about its interest in HCW9218: ir.immunitybio.com which states, in part:
"Under the terms of the Settlement, in part and for no monetary consideration from ImmunityBio, Respondents have transferred and assigned to ImmunityBio molecules (along with other related assets, including master cell banks, clinical trial protocols, inventory and FDA documents), controlled by Respondents that were generated through the use of a tissue factor-based fusion discovery platform (“TF Platform”) related to the human transforming growth factor receptor (“TGFb”) and TGFb traps, including, without limitation, HCW9218, HCW9219, HCW9209 and any derivatives thereof or therefrom, including assignment of all patents, know how and all other intellectual property existing as of the Settlement effective date and thereafter that is necessary or reasonably useful for the exploitation of such TGFb molecules, with the exception that future reasonably useful intellectual property is the subject of a non-exclusive license to ImmunityBio. HCW9218 is a heterodimeric, bifunctional fusion protein complex comprised of extracellular domains of the human TGFb receptor II, as a TGFb trap for TGFb neutralization, and a human interleukin (“IL”)-15/IL-15 receptor a complex for immune cell stimulation, which has been studied in Phase 1/1b clinical trials in ovarian and pancreatic cancer. Respondents have agreed to complete a technology transfer over the 30-day period following the Settlement effective date for purposes of manufacturing the TGFb molecules, which ImmunityBio will control going forward. For indications outside of oncology, ImmunityBio has agreed to grant an exclusive license back to Respondents for the transferred intellectual property for TGFb products, and a non-exclusive license for neoadjuvant ovarian cancer, subject to certain requirements." |
